Home Latest Articles
Latest Articles
  • Yu ZHANG, Jia NIE, Ziyue DANG, Dongmei GUO
    Chinese Journal of Pharmaceuticals. 2026, 57(6): 735-742.
  • Jiahui WANG, Fenghua GU
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 499-507.

    Small interfering RNA(siRNA) is a programmable gene-silencing therapeutic agent that can specifically downregulate the expression of pathogenic genes through the RNA interference mechanism, thereby exhibiting significant potential in precision therapy for respiratory diseases. In recent years, siRNA agents targeting key pathogenic genes in respiratory diseases have shown promising therapeutic efficacy in disease models such as lung cancer, asthma,COPD, and idiopathic pulmonary fibrosis. However, naked siRNA suffers from several limitations, including poor in vivo stability, high susceptibility to nuclease degradation, low transmembrane delivery efficiency, difficulty in penetrating the pulmonary mucus barrier, and inadequate endosomal escape capability, which severely hinder its clinical translation. To address these challenges, various nanoscale delivery systems, including lipid nanoparticles, polymeric nanoparticles, viral vectors, inorganic nanomaterials, and exosomes, have been developed for the efficient delivery of siRNA to pulmonary lesions. Centered on the “disease - siRNA target - delivery system” framework, this review systematically summarizes the research progress of representative siRNA-based nanoscale delivery systems for respiratory diseases. It critically examines how different nanocarriers influence siRNA delivery efficiency with respect to systemic circulation stability, pulmonary targeting, mucus penetration, cellular uptake, and endosomal escape. Furthermore, it outlines optimization strategies such as passive targeting, ligand modification, stimuli-responsiveness, and biomimetic modification, aiming to provide a reference for further research and clinical translation of siRNA therapeutics for lung-targeted treatment of respiratory diseases.

  • Jiahui LI, Zhishang HU, Yafen ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 508-515.

    Polysorbate-degrading enzymes(PSDE) are endogenous protein mixtures secreted by host cell lines during the manufacture of recombinant protein drugs and are unrelated to target products. PSDE degrade common excipients(such as polysorbate 20 and polysorbate 80) in protein formulations, thereby generating fatty acid particles,protein particles, and composite particles, further compromising product safety and reducing shelf-life stability. The detection and quantitative analysis of PSDE are critical steps to ensure drug safety. ELISA and MS are commonly used for PSDE detection. This article reviews the principles of enzymatic hydrolysis of excipients, the classification of PSDE,and commonly used detection methods. It highlights that the development of reference materials is critical for quantitative analysis, providing reference and guidance for subsequent PSDE detection.

  • Kun LUO, Xuyan LIU, Tengda ZHANG, Xiaonan FAN, Guan WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 516-521.

    This study focuses on the synthetic process optimization of elacestrant(1). Starting from 7-benzyloxy-3-bromo-1,2-dihydronaphthalene(2), a one-pot sequence involving the Miyaura reaction and Suzuki cross-coupling reaction with 2-bromo-5-methoxyacetanilide(4) afforded N-[2-[6-(benzyloxy)-3,4-dihydronaphthalen-2-yl]-5methoxyphenyl]-acetamide(5). Compound 5 was reduced with hydrogen under the catalysis of palladium hydroxide on carbon to yield the racemic N-[2-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methoxyphenyl]acetamide(6). Compound 6 underwent deacetylation to yield the racemic compound 6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol(7).Resolution of 7 with L-(–)-dibenzoyl tartaric acid, followed by further resolution with D-(+)-dibenzoyl tartaric acid and basification, furnished (R)-6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol[(R)-7]. Reductive amination of (R)-7 with N-ethyl-2-(4-formylphenyl)acetamide(8) produced N-ethyl-4-[[ethyl[5-methoxy-2-[(2R)-1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl]phenyl]amino]methyl]benzeneacetamide[(R)-9]. Finally, reduction under sodium borohydride/iodine conditions and subsequent salt formation yielded the target product 1. The overall yield was approximately 18%(based on 2), with chemical purity over 99.7% and ee value over 99.99%. This process features mild reaction conditions and stable, controllable product quality.

  • Zhongzhu LONG, Linwang LI, Yong CHEN, Dawei TENG, Shuihong CAI
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 522-526.

    The synthetic process of (3aS,6aR)-9-cis-tetrahydro-4-methoxyfuro[3,4-b]furan-2(3H)-one(1), a key intermediate of an anti-AIDS drug darunavir, was investigated. Compound 5,6-O-isopropylidene-L-ascorbic acid(3)was prepared from L-ascorbic acid(2) via ketalization, which was then subjected to one pot reaction(including hydrogen peroxide oxidation, sodium hypochlorite oxidation and Wittig-Horner reaction) to obtain methyl (R,E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)acrylate(6). After experiencing Michael reaction, Nef reaction and cyclization, the key intermediate of darunavir 1 was obtained with the overall yield of 26.7%(based on 2), with the purity of 99.1% and chiral purity of 99.8%. This synthetic process avoids the hardening of mineral salt on the production device, which is simple to operate with low cost and easy to scale up for industrial production.

  • Qianling YANG, Jia SONG, Hongxia SHEN, Xiaoyun CHAI, Qingjie ZHAO
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 527-536.

    A series of matrine(1) derivatives were designed and synthesized. Based on the tetracyclic rigid scaffold of 1 as the parent core, structural modifications were carried out by introducing a thione group at the C15 position and installing substituted cinnamamidomethyl or heteroaromatic amidomethyl groups at the C13 position. This strategy yielded twelve novel derivatives(B1 - B9 and E1 - E3), whose structures were fully characterized by ¹H NMR,¹³C NMR, and HRMS. The anti-inflammatory activities of these compounds were evaluated in lipopolysaccharide-induced RAW264.7 macrophage cells. At a concentration of 12.5 μmol/L, all derivatives inhibited nitric oxide(NO) production more effectively than the parent compound 1[(41.15±0.23)%]. Notably, compounds B1 - B3 exhibited superior inhibitory activities[(70.40±0.83)%, (71.10±0.69)% and (71.89±0.71)%, respectively]), outperforming the reported positive control 13-methylamino-18-thiomatrine[(64.68±0.39)%]. Structure-activity relationship analysis suggested that introducing a substituted cinnamamidomethyl moiety at C13 enhanced anti-inflammatory potency. Among them, compound B3 demonstrated strong inhibitory effects on key inflammatory mediators, including NO, IL-6, and TNF-α, indicating its potential as a promising anti-inflammatory lead compound for further development.

  • Shuqi LIN, Yapeng WANG, Haoju HUA, Jianguang LU, Jun FENG
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 537-545.

    The preparation of antibody crystallizable fragment(Fc) often relies on costly mammalian cell expression systems, and its complement dependent cytotoxicity(CDC) and antibody-dependent cell-mediated cytotoxicity(ADCC)pose potential safety risks. To address these bottlenecks, this study efficiently produced the Fc variant Fc3(1) in Escherichia coli. This variant exhibits weaker CDC and ADCC effects and reduced hinge region disulfide bonds through amino acid mutations, which is conducive to industrial production. This study systematically optimized process parameters, achieving efficient refolding and separation and purification of 1, with a yield of 407.4 mg/L and a purity of 91.2%. Subsequently, the equilibrium dissociation constant(KD) of 1 binding to neonatal Fc receptor(FcRn) at pH 6.0 was measured to be 10.8 nmol/L using bio-layer interferometry, while the binding was very weak at pH 7.4, demonstrating successful expression of 1 in E. coli and its typical pH-dependent FcRn binding characteristics. This study provides a feasible technical pathway for the low-cost, high-yield production of Fc-like proteins and lays the foundation for the subsequent application of 1.

  • Qian ZHANG, Wenqi LIU, Yuelin FANG, Xinxin ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 546-556.

    Peptide drugs occupy a unique position in the field of tumor therapy due to their high specificity and potent activity. However, their clinical translation and application are often restricted by poor stability and low cellular uptake efficiency. To address this, this study employed the vascular endothelial growth factor A/B antagonistic peptide VGB3 as the model drug, and screened amphiphilic molecules bearing ion-pair structures in combination with salt ions to drive the preparation of VGB3 supramolecular peptide(V-SMP). The average particle size of V-SMP was approximately 150 nm, and it appeared as monodisperse regular spherical particles under a transmission electron microscope and exhibited good stability. Cell experiment results showed that V-SMP increased the uptake efficiency of VGB3 in mouse melanoma cells(B16F10 cells) by 1.49-fold and effectively inhibited tumor cell proliferation. In a subcutaneous syngeneic model of B16F10 melanoma, V-SMP significantly inhibited tumor growth, achieving antitumor efficacy nearly twice that of the free peptide. In summary, this supramolecular peptide formulation improves both the stability and therapeutic activity of peptide drugs, providing a valuable reference for tumor therapy and peptide drug development.

  • Yue YUAN, Chunmei ZHU, Limin SHI, Chuanji YANG, Fuli ZHANG, Haoxiang WU
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 557-561.

    In this study, gellan gum(GG) and hydroxyethyl cellulose(HEC) were used as the composite matrix. With the formulation viscosity at 25 ℃ and the gel viscosity after mixing with simulated tear fluid at 34 ℃ as the response indicators,a central composite design-response surface methodology was adopted to optimize the formulation of ketorolac tromethamine ion-sensitive in situ ophthalmic gels. The final optimized formulation consisted of 0.53% GG and 0.11% HEC.Subsequently, an in vitro release assay based on UV spectrophotometry was established and validated, and the release behavior was evaluated using a modified paddle method. The in situ gels prepared with the optimized formulation achieved a cumulative release rate of over 90% within 8 h, significantly prolonging the drug release time. The release kinetics conformed to the Ritger-Peppas model(Q=5.257 0t0.459 8, R2=0.984 3), indicating that the release mechanism was predominantly Fickian diffusion. The results indicated that the ion-sensitive ophthalmic in situ gels exhibited excellent performance and held promise for improving ocular bioavailability by prolonging corneal retention time.

  • Xiaolong HUANG, Yanping HU, Qian LIU, Zixiu LIU, Lin PAN
    Chinese Journal of Pharmaceuticals. 2026, 57(5): 562-569.

    To address the issue of flurbiprofen menthyl ester impurity formation during long-term storage of flurbiprofen(1) patches, this study prepared 1 patches using maleic anhydride-grafted styrene-isoprene-styrene block copolymer(SIS-MAH) as the matrix skeleton. The formulation was systematically optimized via a Box-Behnken design,with adhesion and in vitro release performance as evaluation indicators. The final optimized formulation was as follows:SIS-MAH of 27.5%, high molecular weight polyisobutylene of 4.96%, low molecular weight polyisobutylene of 6.04%,liquid paraffin of 44.20%, hydrogenated rosin glycerin ester of 11.74%, L-menthol of 2.38%, zinc stearate of 0.5%,and butylated hydroxytoluene of 0.3%. The optimized 1 patches showed key quality attributes comparable to those of the reference listed drug, including drug release behavior, skin permeation performance, and skin adhesion. Preliminary stability test results indicated that the self-developed 1 patches exhibited significant advantages in long-term stability and impurity control, with a markedly lower flurbiprofen menthyl ester content than that of the reference listed drug, demonstrating high safety for clinical application.

News